CClinicalTrials.gg
Status unknownNCT04732234Updated Feb 1, 2021

Pre-emptive US Guided Superior Hypogastric Plexus Block in Pelvic Cancer Surgeries : a Randomized Double-Blinded Study

An interventional study of Superior Hypogastric Plexus Block in Analgesia, sponsored by National Cancer Institute, Egypt. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by National Cancer Institute, Egypt · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The superior hypogastric plexus (SHP) is a retroperitoneal structure with a predominance of afferent sympathetic nerve fibers. The perception of central pelvic pain is thought mainly to involve transmission through this plexus. Therefore, blocking or of SHP has been used to treat pelvic pain.

Read the detailed description

Ultrasound guided superior hypogastric plexus block there is 2 equal groups:

Group S (SHPB group 18 patients) ultrasound guided SHPB is done after induction of balanced general anesthesia (fentanyl, propofol and rocuronium) using 20 ml Bupivacaine 0.5% before skin incision, Group C (Control group 18 patients) in which same technique will be done but using normal saline 0.9% instead of bupivacaine. Patients of both groups will receive patient controlled analgesia using morphine with continous background infusion of morphine 1.5 mg/h with adding granisterone 2mg/60 ml and ability to give bolus of 0.5 mg morphine on demand.

  • Dosing and administration; Group S (SHPB group 18 ultrasound guided SHPB ) using 20 ml Bupivacaine 0.5% before skin incision.

Group C (Control group 18 patients) in which same technique will be done but using normal saline 0.9%

02

Conditions studied

  • Analgesia

Browse trials for

03

In context

Pelvic Neoplasms

98 studies on the registry are indexed under Pelvic Neoplasms; 27 are open to participants now.

This study's planned enrollment of 40 is close to the median of 42 across 63 interventional studies indexed under Pelvic Neoplasms.

Browse Pelvic Neoplasms studies →

Lead sponsor

National Cancer Institute, Egypt is the lead sponsor of 133 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • ASA II,III.
  • Patients undergoing pelvic surgeries.

Exclusion criteria

Exclusion Criteria:

  • Patients refusal,
  • Coagulopathy,
  • Infection.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    ( Group A)

    ultrasound guided superior hypogastric plexus block using 20 ml Bupivacaine 0.5% before skin incision.

    Procedure: Superior Hypogastric Plexus Block

  • Placebo comparator
    (Group B)

    ultrasound guided superior hypogastric plexus block using 20 ml normal saline 0.9% instead of bupivacaine.

    Procedure: Superior Hypogastric Plexus Block

Interventions

  • ProcedureSuperior Hypogastric Plexus Block

    Pre operative ultrasound guided superior hypogastric plexus block in pelvic surgeries using a curvilinear probe below umbalicus with needle in plane technique to reach the plexus in front of L5 vertebra

06

What researchers measure

Primary outcomes

  1. morphine consumption

    Total 24 hours morphine consumption in milligrams

    Time frame: baseline till 24 hours postoperative

Secondary outcomes

  1. Visual analogue scale (VAS)

    scale in which 0 is least pain and 10 is sever pain

    Time frame: Visual analogue scale (VAS) at baseline till 24 hours postoperative

07

Study locations

1 site
  • Nataional Cancer Instituite
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04732234
Lead sponsor
National Cancer Institute, Egypt
Responsible party
Mohammed Abdelfattah Abdelwadod (Mohammed Abdelfattah Abdelwadod, National Cancer Institute, Egypt) — Principal investigator
First posted
Feb 1, 2021
Start date
Dec 1, 2020
Primary completion
May 2021 (estimated)
Completion
May 2021 (estimated)
Last update
Feb 1, 2021

Study contacts

Mohamed abdel wadod, MD
principal investigator · Anesthesia & pain management Dept, National Cancer Institute-Cairo - Egypt

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion